上海交通大学学报(医学版) ›› 2020, Vol. 40 ›› Issue (2): 267-.doi: 10.3969/j.issn.1674-8115.2020.02.021

• 综述 • 上一篇    下一篇

粪菌移植治疗炎症性肠病的研究进展

周 铖1,孙鹏飞2,尹继瑶3,王阳阳1,肖海娟4, 5   

  1. 1. 陕西中医药大学第一临床医学院,咸阳 712000;2. 南京中医药大学第一临床医学院,南京 210000;3. 南京中医药大学翰林学院,泰州 225300;4. 空军军医大学西京消化病医院肿瘤生物学国家重点实验室,西安 710032;5. 陕西中医药大学附属医院肿瘤四科,咸阳 712000
  • 出版日期:2020-02-28 发布日期:2020-03-20
  • 通讯作者: 肖海娟,电子信箱:daisytcm@hotmail.com。
  • 作者简介:周 铖(1995—),男,硕士生;电子信箱: 412973805@qq.com。
  • 基金资助:
    国家自然科学基金(81303135);中国博士后科学基金面上项目(2017M613351);陕西中医药大学创新团队(2019-YL06)。

Evolution of clinical treatment in inflammatory bowel diseasesfecal microbiota transplantation

ZHOU Cheng, SUN Peng-fei, YIN Ji-yao, WANG Yang-yang, XIAO Hai-juan   

  1. 1. The First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712000, China; 2. The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210000, China; 3. Nanjing University of Chinese Medicine Hanlin College, Taizhou 225300, China; 4. State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xian 710032, China; 5. The Fourth Department of Oncology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
  • Online:2020-02-28 Published:2020-03-20
  • Supported by:
    National Natural Science Foundation of China (81303135); General Program of China Post-doctoral Science Foundation (2017M613351); Subject Innovation Team of Shaanxi University of Chinese Medicine (2019-YL06).

摘要: 炎症性肠病 (inflammatory bowel disease,IBD)病因复杂,病理机制尚未完全明确,目前认为病情的进展与肠道菌群的变化有关。常规内科抗炎治疗容易出现较大的不良反应。近年肠道菌群研究的不断深入,为该病提供了新型的治疗方法。粪菌移植(fecal microbiota transplantation,FMT)治疗IBD的多项随机对照临床试验均获得良好的治疗效果,受到国际医学界的广泛关注。该文综述了近5年来FMT的方法学改进、肠功能调控作用机制研究进展,并对FMT研究中的难点和发展方向进行了总结。

关键词: 炎症性肠病, 粪菌移植, 肠道菌群, 免疫调节

Abstract:

The etiology of inflammatory bowel disease (IBD) is complex, and the mechanism has not yet been fully clarified. It is currently believed that the progression of the disease is related to the alterations of intestinal flora. Conventional medical anti-inflammatory treatment has large side effects. In recent years, with the continuous study of intestinal flora, a new kind of therapy has been applied to the disease. Many randomized controlled trials (RCT) of fecal microbiota transplantation (FMT) have achieved good therapeutic effects on IBD, and this regimen has received extensive attention. This paper reviews the progression of FMT and its mechanisms of intestinal function regulation in the past five years. Meanwhile, the challenges and future directions in the research of FMT are also summarized.

Key words: inflammatory bowel disease (IBD), fecal microbiota transplantation (FMT), intestinal flora, immunomodulation